Subject Index to Volume 69

A

Acetylcholine
effect on suprachiasmatic circadian pacemaker, 680–682
release, modulation by presynaptic autoreceptors, 897–911
muscarine receptors, 897–908, 921–922, 936–940, 957–960
nicotine receptors, 908–911, 922, 940, 960–961
somnogenic activity, 639–640
Acid-base balance, ammonium production and excretion and, 239–241
Acidification, vacuolar. *See* Eucaryotic cells, vacuolar acidification
ACTH. *See* Adrenocorticotropic hormone
Action potential
depressed fast responses or slow responses, in acute myocardial ischemia, 1067–1069
duration of, in acute myocardial ischemia, 1070–1072
in heart relaxation, 1259–1262
transmembrane, in acute myocardial ischemia, 1064–1066
Adenosine, somnogenic activity, 638–639
Adenosine diphosphate, platelet activation and, 77–80
Adenosine monophosphate, cyclic
effect on transepithelial ion transport in gallbladder, 533–537
mesangial, 1377, 1379–1380
in platelets, inositol phospholipid metabolism and, 109
Adenosinetriphosphatase
H^+, 778–788. *See also* ATP-driven proton pumps, vacuolar
F_1F_0 class, 776–778. *See also* ATP-driven proton pumps
H^+-translocating, in pH regulation in single cells, 361
phosphorylated, 775–776. *See also* ATP-driven proton pumps
Adenylate cyclase-adenosine 3′,5′-cyclic monophosphate, mesangial, 1377, 1379–1380
Adrenal steroid metabolites, somnogenic activity, 641
Adrenocorticotropic hormone
immunoregulatory functions, 5–7
leukocyte-derived, 15–17
Age, serum osteocalcin and, 1015–1016
Alamethicin, 286
Amebas, cell killing by, 285
Amino acids
excitatory, effect on suprachiasmatic circadian pacemaker, 682–683
human gastrin mRNA, 484
metabolism, hepatic zonation, 726
development and adaptation of zonation, 746–747
zonal flux differences in vitro, 747–748
osteocalcin sequence, 994–995
γ-Aminobutyric acid
effect on suprachiasmatic circadian pacemaker, 683–684
release, modulation by presynaptic autoreceptors, 911–914, 923, 940–941, 961
Ammonia metabolism
enzymes of, hepatic zonation of gene expression for, 737
hepatic zonation, 726
development and adaptation of zonation, 746–747
zonal flux differences in vitro, 747–748
Ammonium transport, nonrenal, 241–243
bacteria and fungi, 243
crab gill, 243
fish gill, 242–243
turtle urinary bladder, 241–242
Ammonium transport, renal, 179–243
ammonium production in kidney, 182–185
countercurrent multiplication of ammonium, 225–228
evidence for, 226–227
physiological importance of medullary ammonium accumulation, 227–228
medullary accumulation of ammonium, 204, 225–228
physiological importance of, 227–228
NH_4^+/NH_3 equilibrium, 180–181
NH_3 transport across plasma membranes and tight junctions, 196–198
NH_4^+ transport across plasma membranes and tight junctions, 190–196

via K^+ pathways, 191–194
via Na^+-H^+ exchanger, 194–195
via tight junctions, 195–196
NH_3 transport across renal tubule epithelia, 212–225
cortical collecting duct, 219–220
disequilibrium pH and, 223–225
distal convoluted tubule, 218–219
inner medullary collecting duct, 221–223
outer medullary collecting duct, 220–221
proximal convoluted tubule, 212–215
proximal straight tubule, 215–217
thick ascending limb, 217
transepithelial NH_3 concentration gradients and, 212–223
NH_4^+ transport across renal tubule epithelia, 205–212
active, 205–210
mediated by Na^+-K^+-ATPase, 210
thick ascending limb of Henle's loop, 205–210
passive, 211–212
proximal convoluted tubule, 211
proximal straight tubule, 211
thick ascending limb, 212
thin limbs of Henle's loop, 212
overview, 238–239
pathways, 198–205
collecting duct system, 202–204
distal loop, 202
glomerulus, 198–199
loop of Henle, 201–202
medullary accumulation of ammonium, 204
proximal tubule, 199–201
physiological importance of renal ammonium excretion, 181
Pitts' view on, 185–190
diffusion trapping theory, 186–187
experimental basis, 187–189
NH_3 as buffer, 189–190
regulation of, 228–238
proximal tubule, 228–234
H^+ concentration, 230
K^+ concentration and, 232–234
luminal flow rate, 229–230
luminal pH and, 231–232
peritubular pH and, 230–231
thick ascending limb, 234–238
independence of NH_4^+ and H^+-HCO_3^- transport, 237–238
K^+ concentration and, 234–236
luminal flow rate and NH_4^+ concentration, 236–237
NaCl absorption and transepithelial voltage, 237
systemic acid-base balance and, 239–241
terminology, 180
Androgens, sebaceous gland activity and, 395–397
Animal models
chronic ventricular arrhythmia, 1115–1116
myocardial infarction, 1121–1127
coronary artery occlusion and reperfusion, 1124–1127
healed infarcts and acute ischemia, 1127
permanent coronary artery occlusion, 1121–1124
ventricular arrhythmia of myocardial ischemia/infarction, 1053–1058
anesthesia and, 1055–1056
isolated Langendorff-perfused hearts, 1057–1058
location of coronary artery occlusion, 1054–1055
mode of coronary artery occlusion, 1053–1054
presence of previous infarction or cardiac hypertrophy, 1056–1057
role of preexisting collaterals, 1055
successive coronary artery occlusions, 1056
Antigens, lymphocyte function-associated, 254–255
Arachidonic acid, platelet activation and, 74–77
Arginine vasopressin
immunoregulatory functions, 10
leukocyte-derived, 18
Arginine vasotocin, somnogenic activity, 635–636
Arteriole
electrical properties, sympathetic innervation and, 572–573
neuromuscular transmission in, 573–586
excitatory junction potentials, 578–586
analysis of, 582–586
properties of, 578–582
quantal count, 583–586
time course of junctional currents, 582–583
properties of neurogenic α-depolarizations, 576–578
sympathetic nerve stimulation and vasoconstriction, 574–576
smooth muscle membrane properties, 550–572

electrical properties dependent on membrane potential, 557–572
calcium-activated K conductance, 566–568
delayed rectification, 563–566
inward rectification, 557–562
voltage-dependent calcium entry, 568–572
passive electrical properties, 553–557
resting membrane potential, 550–553
structure, 548
sympathetic innervation, 548–550
sympathetic neuroeffector transmission in, 546–597
integration, 586–592

Artery
electrical properties, sympathetic innervation and, 572–573
neuromuscular transmission in, 573–586
excitatory junction potentials, 578–586
properties of, 578–582
quantal count, 583–586
time course of junctional currents, 582–583
properties of neurogenic α-depolarizations, 576–578
sympathetic nerve stimulation and vasoconstriction, 574–576
smooth muscle membrane properties, 550–572
electrical properties dependent on membrane potential, 557–572
calcium-activated K conductance, 566–568
delayed rectification, 563–566
inward rectification, 557–562
voltage-dependent calcium entry, 568–572
passive electrical properties, 553–557
resting membrane potential, 550–553
structure, 548
sympathetic innervation, 548–550
sympathetic neuroeffector transmission in, 546–597
integration, 586–592

ATP-driven proton pumps
classes, 775
F_1F_0 class of H^+-ATPases, 776–778
inhibitor specificity and ion transport properties, 779
structure and subunit function, 782
phosphorylated ATPases, 775–776
inhibitor specificity and ion transport properties, 779
structure and subunit function, 782
vacuolar. *See* ATP-driven proton pumps, vacuolar

ATP-driven proton pumps, vacuolar, 765–766
functions of vacuolar acidification, 766–775. *See also* Eucaryotic cells, vacuolar acidification
inhibitor specificity, 778, 779, 780
ion transport specificity, 779, 780–781
relationship and regulation, 786–788
structural properties, 781, 782, 783–785
subunit function, 785–786

Atrial contraction, during diastole, 1286

Auxotonic, definition, 1297

B

Bacteria, ammonium transport, 243

Basal cell proliferation, 1318

Bicarbonate, effect on transepithelial ion transport in gallbladder, 537–539

Bile formation, hepatic zonation, 728–729, 750
uptake and secretion of bile salts, 750
uptake and secretion of various substances, 750–751

B lymphocytes, 3–4, 254
proliferation, activation of, 419

Bone, vitamin K-dependent proteins in. *See* Matrix Gla protein; Osteocalcin

Bone disease, serum osteocalcin and, 1018–1026

Bone resorption, osteocalcin and, 1031–1033

Bradycardia, ventricular arrhythmia of myocardial ischemia and, 1089–1092

Brain
glucose metabolism, sleep-induced changes, 634–635
mRNA, sleep and, 619
suprachiasmatic nuclei. *See* Suprachiasmatic nuclei

C

Calcitonin, serum osteocalcin and, 1028

Calcium
intracellular
effect on transepithelial ion transport in gallbladder, 539–540
in mesangial cells, 1384–1388
keratinocyte differentiation and, 1334–1335
osteocalcin interactions, 996–999
platelet activation and, 123–141
calcium-dependent processes within platelet, 126–129
calcium in stimulated platelets, 133–137

calcium in unstimulated platelets, 130–133
general considerations, 123–126
platelet function and, 137–141
aggregation, 140–141
effect of calcium ionophores and intracellular calcium chelators, 137–138
secretion, 139–140
shape change, 138–139
somnogenic activity, 641–642
in target cell killing by lymphocytes, 255–256
transport, in lymphocytes, 456–466
Calcium-binding protein, skin, 1330
Calmodulin, in platelets, 126
Calpains, in platelets, 126
Carbohydrate metabolism
enzymes of, hepatic zonation of gene expression for, 734–737
hepatic zonation, 718–719, 724
development and adaptation of zonation, 738–739
zonal flux differences in vitro, 742–745
zonal flux differences in vivo, 739–741
γ-Carboxyglutamic acid (Gla) protein
bone. *See* Osteocalcin
matrix. *See* Matrix Gla protein
Cardiomyopathy
hypertrophic, relaxation and diastole in, 1290–1291
ischemic, relaxation and diastole in, 1289–1290
valvular, relaxation and diastole in, 1291–1292
Catecholamines, somnogenic activity, 640
Cell volume regulation
membrane mechanisms in, 315–359
ion transport systems in, 316, 318–320
regulatory volume decrease, 320–344
activation mechanisms, 340–344
Ehrlich ascites tumor cells, 322–330
K^+-Cl^- cotransport, 332–337
K^+-H^+ exchange functionally coupled to Cl^--HCO_3^- exchange, 338–339
lymphocytes, 330–332
transport of amino acids and taurine, 339–340
volume-activated Cl^- and K^+ conductance pathways, 322–332
regulatory volume increase, 344–359
activation mechanisms, 358–359
Na^+-H^+ exchange functionally coupled to Cl^--HCO_3^- exchange, 353–357
volume-activated cotransport, 346–353
Chemoreceptors, laryngeal, 47–48
Chloride
transepithelial transport in gallbladder, 506–509
across apical membrane, 517–529
across basolateral membrane, 529–532
transport, in lymphocytes, 468–471
transport systems involved in cellular volume and pH regulation, 318–320
Cholecystokinin octapeptide, somnogenic activity, 637
Cholera toxin, keratinocyte differentiation and, 1333
Cholesterol synthesis, hepatic zonation, 725–726
Chorionic gonadotropin, leukocyte-derived, 17–18
Chorionic gonadotropin, human, immunoregulatory functions, 12
Circadian pacemaker, suprachiasmatic, 671–699
efferents of suprachiasmatic nuclei, 696–699
functional considerations, 698–699
neuroanatomy, 697–698
neuropharmacology, 698
input of, 674–684
functional significance of afferent pathways, 677–680
geniculohypothalamic tract, 677–678
raphe afferents, 678–679
retinohypothalamic tract, 679–680
identification of neural afferents, 674–676
pharmacologic manipulation of circadian rhythms, 680–684
acetylcholine, 680–682
γ-aminobutyric acid, 683–684
excitatory amino acids, 682–683
visual properties of suprachiasmatic nuclei, 676–677
machinery of, 693–696
role of action potentials in generation of rhythmicity, 695–696
organization of, 684–696
electrical activity of suprachiasmatic nuclei, 689–693
suprachiasmatic nuclei responsiveness to putative neurotransmitters, 691–692
similarities between suprachiasmatic nuclei and other brain areas, 692–693
spontaneous discharge of suprachiasmatic cells, 689–691
evidence for suprachiasmatic nuclei as pacemaker, 684–687

machinery of circadian pacemaker, 693–695
morphology and anatomy of suprachiasmatic nuclei, 687–689
Colicins, 286–287
Collagen, platelet activation and, 69–71
Complement system, membrane attack complex, similarities and differences with perforin, 280–284
Coronary artery occlusion. *See* Myocardial ischemia/infarction
Cough, laryngeal respiratory functions and, 45
Crab gill, ammonium transport, 243
Cytidine, somnogenic activity, 619

D

Diabetes mellitus, serum osteocalcin and, 1029
Diacylglycerol, exogenous, platelet activation and, 117–119
1,2-Diacylglycerol, platelet activation and, 105
Diamphotoxin, 286
Diastasis, definition, 1298
Diastole. *See* Heart, diastole
Diet
foods containing riboflavin and vitamin B_6, 1174–1175
serum osteocalcin and, 1016–1017
Digestion and absorption, riboflavin and vitamin B_6 compounds, 1175–1176
Dopamine, release, modulation by presynaptic autoreceptors, 874–883, 917, 919, 930–933, 948–952

E

Effectors, potential oncogenicity, 809–810
Ehrlich ascites tumor cells
regulatory volume decrease
K^+-Cl^- cotransport, 336–337
volume-activated Cl^- and K^+ conductance pathways, 322–330
regulatory volume increase, 347–351
Electrical field effects, 821–857
central structures exhibiting, 840–848
cerebellar cortex (rat), 841
cerebral cortex, 848
hippocampus, 841–842
normal conditions, 842–845
pathological conditions, 845–847
olfactory bulb, 847
retina, 847–848
spinal cord, 840
conditions favoring, 831–840
cellular orientation, 834–835
degree of neuronal activity, 835–836
extracellular resistivity, 833–834
field strength and detection of electrical interactions, 839–840
passive membrane properties, 836–839
consequences for neuronal electrical activity, 851–853
comparison with chemical transmission, 852–853
importance for synchrony, 851–852
exogenously applied fields, effects on excitability of central neurons, 848–851
historical perspective, 823–825
influence on cell growth and membrane differentiation, 853–857
evaluation of underlying event, 855–857
macroscopic effects on development, 853–855
Mauthner (M) cell model, 825–831
electrical inhibition: sign inversion of presynaptic impulses, 828–830
localized resistive barriers in, 828
spatial distribution of field potentials, 825–828
tests for assessing, 830–831
Electroencephalogram, slow-wave activity, measure of sleep intensity, 608–610
Endocytosis
mesangial cell, 1407–1410
in vitro, 1409–1410
in vivo, 1407–1409
receptor-mediated, vacuolar acidification and, 766–771
Endoperoxides, platelet activation and, 74–77
Endorphins
immunoregulatory functions, 7–9
leukocyte-derived, 15–17
Energy metabolism, oxidative, hepatic zonation, 717–718
Enkephalins
immunoregulatory functions, 7–9
leukocyte-derived, 17
somnogenic activity, 637
Enzymes
for ammonia metabolism, gene expression, hepatic zonation of, 737
for carbohydrate metabolism, gene expression, hepatic zonation of, 734–737
hepatic, zonation of, 716, 720–723

for xenobiotic metabolism, gene expression, hepatic zonation of, 737
Eosinophil cationic protein, 284
Epidermal growth factor, keratinocyte differentiation and, 1333
Epidermis, 1316, 1317. *See also* Keratinocyte
Epinephrine
keratinocyte differentiation and, 1333
platelet activation and, 84–89
release, modulation by presynaptic autoreceptors, 873–874, 917, 930, 947–948
Erythropoietin, mesangial synthesis, 1372–1373
Estrogens, sebaceous gland activity and, 397, 401–402
Eucaryotic cells
vacuolar acidification, 766–775
intracellular membrane traffic and, 771–772
lysosomes and digestive vacuoles, 773
plasma membrane and, 773–775
receptor-mediated endocytosis and, 766–771
background, 766–767
clathrin-coated vesicles and CURL, 770–771
ligand-receptor dissociation, 767–769
site of acidification, 769–770
secretory granules, 772–773
vacuolar ATP-driven proton pumps, 765–789. *See also* ATP-driven proton pumps, vacuolar
Excitatory junction potentials
of arteries and arterioles, 578–586
properties of, 578–582
quantal count, 583–586
time course of junctional currents, 582–583
sympathetic transmitter underlying, 592–595
Exercise, serum osteocalcin and, 1017–1018

F

Factor S, somnogenic activity, 614–615
Feline purring, 44
Fetal warfarin syndrome, serum osteocalcin in, 1025–1026
Fibrinogen, platelet activation and, 89–92
Filaggrin, 1329–1330
Fish gill, ammonium transport, 242–243
Flavins
in erythrocytes, 1178
natural forms, 1172–1173
in plasma, 1177
tissue uptake and release, 1179–1181
Flight, optimization and gaits in, 1218–1221
Fractures, serum osteocalcin in, 1020
Fungi, ammonium transport, 243

G

Gait. *See* Locomotion in vertebrates
Gallbladder, transepithelial ion transport, 503–541
early studies, 504–509
electrodiffusive, 509–515
apical cell membrane, 511–513
basolateral cell membrane, 513–515
paracellular pathway, 509–511
electroneutral mechanisms, 515–532
Na^+ and Cl^- transport across apical membrane, 517–529
Na^+ and Cl^- transport across basolateral membrane, 529–532
leaky epithelia, 506–509
regulation of, 532–540
cyclic AMP and, 533–537
HCO_3^- and, 537–539
intracellular calcium activity and membrane transport, 539–540
regulation of paracellular ion permeability, 532–533
two-membrane hypothesis, 504–506
Gastrin, 482–485
biosynthesis, 499
developmental considerations, 499–500
posttranslational processing, 482–501
preprogastrin, 486–489
progastrin-processing intermediates, 489–499
biological activity, 498–499
immunohistochemistry, 494
secretion, 494, 496–498
tissue extracts, 489–494
structure, 485–486
Gene expression
hepatic zonation, 734–737
enzymes of ammonia metabolism, 737
enzymes of carbohydrate metabolism, 734–737
enzymes of xenobiotic metabolism, 737
oncogenesis and, 810–812
Glucocorticoids, sebaceous gland activity and, 398
Gluconeogenesis, hepatic zonation, 724
Glucose metabolism, cerebral, sleep-induced changes, 634–635

Glycogen metabolism, hepatic zonation, 718–719
Glycolysis, hepatic zonation, 719, 724
Glycoprotein Ib, 72
  von Willebrand factor binding to platelets and, 67
Glycoprotein IIb/IIIa complex, 90–92
  von Willebrand factor binding to platelets and, 68
Glycoprotein V, 73
G proteins, platelet activation and, 93–97
Granulocytes, 4–5
Growth factors
  autocrine expression, oncogenes and, 812–813
  potential oncogenicity, 800–802
Growth hormone
  immunoregulatory functions, 9–10
  leukocyte-derived, 17
  somnogenic activity, 633
Growth hormone-releasing factor, somnogenic activity, 633–634
Guanine nucleotide-binding proteins. *See* G proteins
Guanosine monophosphate, cyclic, mesangial, 1380–1381
Guanylate cyclase-guanosine 3',5'-cyclic monophosphate, mesangial, 1380–1381

H

Heart
  arrhythmias. *See* Ventricular arrhythmia
  diastole, 1228–1231, 1282–1297
    age-related changes, 1287–1288
    definition, 1282, 1298
    disease-related changes, 1288–1289
    extraventricular factors during, 1285–1287
      atrial contraction, 1286
      ventricular interaction and pericardial constraint, 1286–1287
    in hypertrophic cardiomyopathy, 1290–1291
    in ischemic cardiomyopathy, 1289–1290
    of isolated cardiac muscle, 1282–1283
      myocardial tone, 1282–1283
      resting length-force relation, 1283
    measurements or indexes of, 1292–1295
    pathophysiological considerations, 1287–1295
    in valvular cardiomyopathy, 1291–1292
    ventricular factors during, 1283–1285
      coronary perfusion pressure and flow, 1285
      tissue elasticity and ventricular configuration, 1284–1285
  as integrated muscle-pump system, 1231–1233
  relaxation, 1233–1281
    age-related changes, 1287–1288
    disease-related changes, 1288–1289
    in hypertrophic cardiomyopathy, 1290–1291
    of intact ventricle, 1264–1282
      load dependence, description, 1264–1267
      load dependence, determinants of, 1267–1282
    in ischemic cardiomyopathy, 1289–1290
    in isolated cardiac muscle, 1235–1263
      action potential and, 1259–1262
      load dependence, description of, 1235–1238
      load dependence, mechanisms of, 1238–1259
      load dependence and shortening inactivation of contraction, 1262–1263
    measurements or indexes of, 1292–1295
    pathophysiological considerations, 1287–1295
    in valvular cardiomyopathy, 1291–1292
Hemodynamics, intraglomerular, mesangial uptake of circulating macromolecules and, 1407
Henderson-Hasselbalch equation, 181
Hepatocyte heterogeneity, 711–752
  study methods, 711–716
    histology and histochemistry, 711–712
    microdissection and microbiochemistry, 712
    noninvasive techniques, 715–716
    orthograde and retrograde liver perfusion, 715
    redox scanning, 716
    selective zonal damage, 714–715
    separation of periportal and perivenous hepatocytes, 713–714
  zonation of enzyme content and subcellular structures, 716–730
    amino acid and ammonia metabolism, 726
    bile formation, 728–729
    carbohydrate metabolism, 718, 724
    cholesterol synthesis, 725–726
    diverse functions, 730
    gluconeogenesis, 724
    glycogen metabolism, 718–719
    glycolysis, 719, 724
    ketogenesis, 725

lipid metabolism, 724–726
lipogenesis, 725
lipoprotein metabolism, 725
oxidative energy metabolism, 716–717
plasma protein synthesis and degradation, 729–730
protective metabolism, 727–728
xenobiotic metabolism, 726–727
zonation of functions, 737–751
amino acid and ammonia metabolism, 746–748
bile formation, 750–751
carbohydrate metabolism, 738–745
lipid metabolism, 745–746
xenobiotic metabolism, 748–749
zonation of gene expression, 734–737
enzymes of ammonia metabolism, 737
enzymes of carbohydrate metabolism, 734–737
hormone gradients, 735–736
innervation, 737
oxygen gradients, 734–735
enzymes of xenobiotic metabolism, 737
zonation of signal input and transmission, 730–734
cellular transmission, 733–734
humoral input, 730–732
hormone gradients, 732
oxygen and substrate/product gradients, 730–732
nervous input, 732–733

Hepatocyte-stimulating factor, hormonal effects, 15

Hiccups, laryngeal respiratory functions and, 44

Histamine, release, modulation by presynaptic autoreceptors, 894–896, 921, 936, 956

Hormones
in hepatic carbohydrate metabolism, 732
hepatic gene expression for enzymes of carbohydrate metabolism and, 735–736
hormonal functions of products of immune system, 12–15
peptide. *See* Peptide hormones

Hydrocortisone, keratinocyte differentiation and, 1333

Hydrogen, transport systems involved in cellular volume and pH regulation, 318–320

Hypercapnia, laryngeal breathing movements in, 41–42

Hyperpnea, laryngeal breathing movements in, 41–42

Hyperproliferative diseases, of epidermis, 1340–1341

Hyperventilation, voluntary, laryngeal breathing movements in, 43

Hypoxia, laryngeal breathing movements in, 42

I

Immune system. *See also* Neuroimmunoendocrinology
bidirectional communication with neuroendocrine systems, molecular basis for, 1–28
cellular components, 2–5
B lymphocytes, 3–4
granulocytes, 4–5
monocytes/macrophages, 4
natural killer cells, 4
T lymphocytes, 2–3
in vitro regulation by neuroendocrine peptide hormones, 5–12
adrenocorticotropic hormone, 5–7
arginine vasopressin and oxytocin, 10
endorphins and enkephalins, 7–9
growth hormone, 9–10
human chorionic gonadotropin, 12
substance P and somatostatin, 11
thyrotropin, 9
vasoactive intestinal peptide, 11–12
in vivo regulation by neuroendocrine system, 24–25
lymphocyte-mediated killing of target cells, 250–301. *See also* Natural killer cells; T lymphocytes, cytotoxic
neuroendocrine peptide hormone receptors, 21–23
products, hormonal functions, 12–15
sensory function, 25–27

Infant, newborn, laryngeal respiratory functions in, 49–51

Inositol phosphates, metabolism, in platelets, 102–105

Inositol phospholipid metabolism, 98–111
general considerations, 98
inositol phosphates, 102–105
phosphatidylinositol, 100–101
phospholipase C in, 98–100
platelet function and, 109–111
aggregation, 111
secretion, 110–111
shape change and adhesion, 110

polyphosphoinositides, 101–102
regulation, 108–109
second messengers and mediators, 105–108
1,2-diacylglycerol, 105
inositol 1,4,5-trisphosphate, 105–107
lysophosphatidic acid, 107–108
phosphatidic acid, 107
Inositol 1,4,5-trisphosphate, platelet activation and, 105–107
Insulin
sebaceous gland activity and, 399
somnogenic activity, 634
Insulin-like growth factor I, mesangial synthesis, 1375
Interferon
hormonal effects, 13–14
γ-interferon, 3
α-interferon, 4
somnogenic activity, 643
Interleukin 1
hormonal effects, 14
mesangial synthesis, 1373–1374
somnogenic activity, 642–643
Interleukin 2, 3
hormonal effects, 15
Involucrin, 1323–1326
Ion transport systems
gallbladder epithelium, 503–541. *See also* Gallbladder, transepithelial ion transport
in lymphocytes, 430, 432–471
calcium, 456–466
chloride, 468–471
magnesium, 466–468
potassium, 446–456
sodium, 432–446
in volume and pH regulation in vertebrate cells, 318–320

K

47-kDa protein, platelet, phosphorylation, 115–117, 118
Keratinocyte
differentiation, 1317–1341
abnormal, 1339–1341
hyperproliferative disease, 1340–1341
squamous cell carcinoma, 1340
virus infection, 1339–1340
biochemical changes during, 1336–1339
calcium and, 1334–1335
cholera toxin and, 1333
epidermal growth factor and, 1333
epinephrine and, 1333
factors regulating, 1330–1335
hydrocortisone and, 1333
morphological changes during, 1317–1320
basal cell layer, 1317–1318
cornified layer, 1319–1320
granular layer, 1319
spinous layer, 1319
transition zone, 1319
terminal, events during, 1338–1339
terminal, preparation for, 1336–1338
tumor growth factor-α and, 1333
vitamin A and, 1330–1332
vitamin D and, 1332–1333
proteins, 1320–1330
filaggrin, 1329–1330
involucrin, 1323–1326
keratins, 1320–1323
membranous components of cornified envelope, 1326–1327
skin calcium-binding protein, 1330
structure, during differentiation, 1317–1320
transglutaminase activity, 1327–1329
Keratins, 1320–1323
Ketogenesis, hepatic zonation, 725
Kidney
ammonium production, 182–185
ammonium transport, 179–243. *See also* Ammonium transport, renal
mesangial cell physiology, 1347–1412. *See also* Mesangial cell; Mesangium

L

Lactation, serum osteocalcin in, 1017
Larynx
laryngeal afferents and their reflex actions, 46–49
chemoreceptors, 47–48
mechanoreceptors, 46–47
responses to laryngeal stimulation, 48–49
respiratory functions, 33–51
comparative respiratory physiology, 34–35
infant larynx, 49–51
laryngeal afferents and their reflex actions, 46–49
respiratory movements of mammalian larynx, 35–46
respiratory movements of mammalian larynx, 35–46
in coughing, 45
feline purring, 44

functional anatomy and experimental methods of study, 35–39
in hiccups, 44
hyperpneic states, 41–42
mechanical loads, 43–44
physiological significance, 45–46
quiet breathing, 39–40
reflex modification of breathing movements, 40–41
in sleep, 42–43
in vocalization, 45
voluntary breathing efforts, 43
stimulation, reflex responses, 48–49
Leukocytes. *See also* Immune system, cellular components
neuroendocrine peptide hormone production. *See* Peptide hormones, leukocyte-derived
Leukoregulin, in lymphocyte killing of target cells, 300
Lipid A, somnogenic activity, 644
Lipid metabolism, hepatic zonation, 724–726
development and adaptation of zonation, 745–746
zonal flux differences in vitro, 746
Lipids, bioactive, mesangial synthesis, 1375–1377
Lipogenesis, hepatic zonation, 725
Lipopolysaccharide, somnogenic activity, 644
Lipoprotein metabolism, hepatic zonation, 725
Liver
functions, 708–709
hepatocyte populations, functional specialization. *See* Hepatocyte heterogeneity
innervation, 732–733
structure, 709–711
Locomotion of vertebrates
flight, 1218–1221
optimization and gaits in, 1199–1225
definition of gait, 1200
optimization criteria, 1200–1204
similarity criteria, 1204–1206
swimming, 1221–1224
walking and running, 1207–1218
people and animals, 1207–1216
robots, 1216–1218
Lusitropic, definition, 1298
Lymphocytes
B. *See* B lymphocytes
calcium transport, 456–466
Ca^{2+}-ATPase, 457
Ca^{2+} channels, 458–459
cellular and cytosolic free Ca^{2+} content, 456–457
changes during activation and biological significance, 459–466
intracellular concentration and membrane transport systems, 456–459
chloride transport, 468–471
biological significance of anion transport, 471
intracellular concentration and membrane transport systems, 468–470
volume-induced, 469–470
granule exocytosis, in target cell killing, 262–265
granules, isolation and membrane lytic properties, 269–273
$H^+(OH^-)$ ion transport, 430
ion transport, 417–418, 430, 432–471
killing of target cells, 250–301
calcium-independent mechanism, 291–293
defined granule mediators in, 269–291
analogies between perforin and other pore formers, 284–287
homologies between perforin and membrane attack complex of complement, 280–284
pore-forming protein perforin, 273–280
resistance of killer lymphocytes to their own perforin, 287–289
discrete stages of, 254–257
granule exocytosis in, 262–265
granule isolation and their membrane lytic properties, 269–273
internal disintegration or induced suicide model for, 265–269
mechanistic view, 250–301
membrane damage and pore-formation model, 257–262
nature of lethal hit, 257–269
perforin-independent pathways, 291–300
candidate mediators for, 293–297
leukoregulin in, 300
lymphotoxin-like molecules in, 293–297
phospholipases in, 299
proteoglycans in, 300
serine esterases in, 297–299
physiological role of perforin in, 289–291
magnesium transport, 466–468
changes during activation and biological significance, 467–468
intracellular concentration and membrane transport systems, 466–467

membrane potential, 419–427
biological significance in lymphocyte activation, 425–427
changes associated with activation, 422–425
study methods, 419–420
unstimulated lymphocytes, 421–422
natural killer cells. *See* Natural killer cells
pH, intracellular, 427–432
buffering power and, 429
changes during activation and biological significance, 430–432
H^+ transport, 430
measurement techniques, 427–429
potassium transport, 446–456
Ca^{2+}-activated K^+ channels, 447–449
changes during activation and biological significance, 453–456
intracellular concentration and membrane transport systems, 446–453
voltage-gated K^+ channels, 449–450
volume-sensitive transport, 450–453
proliferation, activation of, 418–419
regulatory volume decrease in, volume-activated Cl^- and K^+ conductance pathways, 330–332
regulatory volume increase in, 355–356
sodium transport, 432–446
changes during activation and biological significance, 438–446
intracellular concentration and membrane transport systems, 432–438
Na^+ conductance, 432–433
Na^+-H^+ exchange, 433–437
Na^+-K^+ pump, 433
Na^+-Na^+ exchange, 437
subsets, 251–254
T. *See* T lymphocytes
Lymphokines, 3
neuroendocrine effects, 13–15
production by neuroendocrine system, 20–21
Lymphotoxin, in lymphocyte killing of target cells, 293–294
Lysophosphatidic acid, platelet activation and, 107–108

M

Magnesium, transport, in lymphocytes, 466–468
Malignancy
skeletal, serum osteocalcin in, 1020–1021
skin, keratinocytes in, 1340
Matrix Gla protein, 999–1001
Mechanoreceptors, laryngeal, 46–47
Meibomian glands, function, 405
Melatonin, somnogenic activity, 640–641
Melittin, 285–286
Membrane potential
lymphocytes, 419–427
biological significance in lymphocyte activation, 425–427
changes associated with activation, 422–425
study methods, 419–420
unstimulated lymphocytes, 421–422
resting
in acute myocardial ischemia, 1058–1064
arterial and arteriolar smooth muscle, 550–553
Mesangial cell, 1348
biosynthetic activity, 1370–1377
bioactive lipids, 1375–1377
enzymes, 1370–1372
erythropoietin, 1372–1373
hormones and cytokines, 1372–1375
insulin-like growth factor I, 1375
interleukin 1, 1373–1374
neutral proteinase, 1371–1372
5′-nucleotidase, 1372
plasminogen activator/inhibitors, 1372
platelet-activating factor, 1375–1376
platelet-derived growth factor, 1374–1375
renin, 1370–1371
contraction, 1396–1403
in vivo, 1402–1403
mechanisms of shape change, 1398–1400
nonhomogeneity of contractile responses, 1400–1402
shape changes in vitro, 1397–1398
extraglomerular, 1353–1354
hormonal control of, 1377–1396
adenylate cyclase-adenosine 3′,5′-cyclic monophosphate, 1377, 1379–1380
guanylate cyclase-guanosine 3′,5′-cyclic monophosphate, 1380–1381
phospholipases C and A_2, 1381–1395
intrinsic, morphology, 1348–1353
phagocytic properties, 1353
processing of circulating macromolecules, 1403–1411
endocytosis in vitro, 1409–1410
endocytosis in vivo, 1407–1409
Fc receptors and reactive oxygen species, 1410–1411
prostaglandin synthesis, 1391–1395
shape change. *See* Mesangial cell, contraction

tissue culture, 1354–1361
biosynthesis of matrix components by cultured cells, 1367–1370
biosynthetic profile, 1357–1358
cell metabolism and physiology, 1357–1358
cell morphology, 1355–1356
experiments with cultured cells, 1361
factors regulating cell growth, 1358–1361
identification and characterization of cells, 1355–1358
immunocytochemistry, 1356–1357
techniques, 1354–1355
Mesangium, 1347–1348
matrix, 1361–1370
biochemical composition, 1363–1367
components, biosynthesis by cultured mesangial cells, 1367–1370
morphology, 1348–1353
structural organization, 1362
structure and ultrastructure, 1348–1354
bone marrow-derived macrophages, 1353
extraglomerular mesangial cells, 1353–1354
intrinsic mesangial cell and mesangial matrix, 1348–1353
uptake of macromolecules, 1403–1411
endocytosis by mesangial cells, 1407–1410
entry of macromolecules, 1404–1405
Fc receptors and reactive oxygen species, 1410–1411
regulation of entry, 1405–1407
intraglomerular hemodynamic factors, 1407
physicochemical characteristics, 1405–1406
1-Methylheptyl-γ-bromoacetate, somnogenic activity, 642
Modulators, potential oncogenicity, 806–809
Monocytes/macrophages, 4
Monokines
neuroendocrine effects, 13–15
production by neuroendocrine system, 20–21
Muramyl peptides, somnogenic activity, 615–617
Myocardial ischemia/infarction
acute phase
electrophysiological effects, 1058–1076
action potential duration and recovery of excitability, 1070–1072
conduction, 1073–1075
depressed fast responses or slow responses, 1067–1069
inhomogeneity, 1072–1073
resting membrane potential, 1058–1064
transmembrane action potential, 1064–1066
ventricular arrhythmias in, 1051–1099
animal models, 1053–1058
heart rate and, 1089–1092
injury currents and, 1085–1087
mechanical malfunction and, 1092
mechanisms of, 1076–1098
nonreentrant mechanisms, 1082–1085
phases of early arrhythmia, 1076–1079
Purkinje system in, 1087–1089
reentry and, 1079–1082
reperfusion arrhythmias, 1092–1095
sympathetic nervous system in, 1095–1098
chronic ventricular arrhythmias after, 1111–1151
animal models, 1115–1116
characteristics of, 1112–1115
electrophysiological properties of healing/healed infarcts, 1127–1140
inducible, 1116–1121
infarct models, 1121–1127
mechanisms of, 1140–1149
healed infarct, electrophysiological properties, 1135–1139
endocardial border zone, 1137–1139
subepicardial muscle, 1135–1137
healing infarction, electrophysiological properties, 1127–1135
subendocardium, 1135
subepicardial muscle, 1128–1135
subacute phase, delayed ventricular arrhythmias in, 1099–1111
electrophysiological properties of Purkinje fibers, 1103–1108
mechanisms of, 1108–1111
origin of arrhythmias, 1102–1103
time course and characteristics, 1099–1102
Myosin, platelet, phosphorylation, 113–115
Myosin light-chain kinase, platelet myosin phosphorylation, 113–115

N

Na^+-H^+ exchange system, in pH regulation in vertebrate cells, 361–369
Natural killer cells, 4, 251, 252–253. *See also* Lymphocytes, killing of target cells
Natural killer cytotoxic factor, in lymphocyte killing of target cells, 294
Nervous system, central, electrical field effects, 821–857. *See also* Electrical field effects

central structures exhibiting, 840–848
conditions favoring, 831–840
consequences for neuronal electrical activity, 851–853
exogenously applied field effects on excitability of central neurons, 848–851
historical perspective, 823–825
influence of fields on cell growth and membrane differentiation, 853–857
Mauthner (M) cell model, 825–831
Nervous system, sympathetic, in ventricular arrhythmia of myocardial ischemia, 1095–1098
Neuroendocrine system. *See also* Neuroimmunoendocrinology
bidirectional communication with immune system, molecular basis for, 1–28
in vivo immunoregulation by, 24–25
peptide hormones. *See* Peptide hormones
production of lymphokines/monokines, 20–21
Neuroimmunoendocrinology, 1–28
biochemical integration of neuroendocrine and immune system circuitry by common receptors and ligands, 24
cellular components of immune system, 2–5
hormonal functions of products of immune system, 12–15
in vitro immunoregulatory functions of neuroendocrine peptide hormones, 5–12
adrenocorticotropic hormone, 5–7
arginine vasopressin and oxytocin, 10
endorphins and enkephalins, 7–9
growth hormone, 9–10
human chorionic gonadotropin, 12
substance P and somatostatin, 11
thyrotropin, 9
vasoactive intestinal peptide, 11–12
in vivo immunoregulation by neuroendocrine system, 24–25
peptide hormone receptors common to immune and neuroendocrine systems, 21–24
production and structure of leukocyte-derived peptide hormones, 15–18
production of lymphokines/monokines by neuroendocrine system, 20–21
regulation and processing of leukocyte-derived peptide hormones, 18–20
sensory function for immune system, 25–27
Neurophysin, leukocyte-derived, 18
Neurotransmitter release, modulation by presynaptic autoreceptors, 864–962
acetylcholine neurons, 897–911
muscarine receptors, 897–908, 921–922, 936–940, 957–960
nicotine receptors, 908–911, 922, 940, 960–961
γ-aminobutyric acid neurons, 911–914, 923, 940–941, 961
definition and determination of release, 866–867
dopamine neurons, 874–883, 917, 919, 930–933, 948–952
epinephrine neurons, 873–874, 917, 930, 947–948
evidence for, 867–915
histamine neurons, 894–896, 921, 936, 956
location of, 915–923
norepinephrine neurons, 870–873, 917, 927–930, 944–947
opioid peptide neurons, 914–915, 923, 941, 961–962
origins of, 865
physiology of, 941–962
serotonin neurons, 883–894, 919–921, 933–935, 952–956
signal transduction, 923–941
Neutral proteinase, mesangial synthesis, 1371–1372
Norepinephrine, release, modulation by presynaptic autoreceptors, 870–873, 917, 927–930, 944–947
5′-Nucleotidase, mesangial synthesis, 1372

O

Oncogenes, cellular signal transduction and, 797–815. *See also* Signal transduction, cellular
Opioid peptides, release, modulation by presynaptic autoreceptors, 914–915, 923, 941, 961–962
Optimization. *See* Locomotion in vertebrates
Osteoblasts
osteocalcin biosynthesis and, 1001. *See also* Osteocalcin, biosynthesis
phenotypic variants in lineage, 1007
Osteocalcin, 990–992
biosynthesis, 1001–1011
bone specificity of, 1005–1006
Gla residues and protein secretion, 1004–1005
modulation of, 1008–1011
osteoblast and, 1001
pathway, 1002–1003

temporal and spatial correlation with bone development and mineralization, 1007–1008
vitamin K-dependent carboxylation of osteocalcin precursor, 1003–1004
as bone matrix component, 992–994
catabolism, clearance, and urinary Gla, 1013–1015
functions, 1029–1033
Gla helix domain as determinant of Ca^{2+} binding, 1030–1031
as mediators of bone-resorptive stimuli, 1033
recruitment and activation of bone-resorbing cells and, 1031–1033
gene, 1001–1002
origin of serum osteocalcin, 1012–1013
properties, 992
serum levels
age and sex and, 1015–1016
in bone disease, 1018–1026
calciotropic hormone effects, 1026–1029
circadian rhythm, 1016
clinical significance of, 1011–1029
diabetes mellitus and, 1029
diet and, 1016–1017
exercise and weightlessness and, 1017–1018
in fractures, 1020
in malignancies, 1020–1021
measurement of, 1011–1012
normal physiological determinants, 1012–1018
in osteogenesis imperfecta, osteochondroplasias, and fetal warfarin syndrome, 1025–1026
in osteoporosis, 1021–1023
in Paget's disease, 1023–1024
parathyroid hormone and calcitonin effects, 1027–1028
in pregnancy and lactation, 1017
race and, 1017
in renal osteodystrophy, 1024–1025
thyroid disorders and, 1028–1029
vitamin D effects, 1026–1027
structure, 994–999
amino acid sequence, 994–995
conformational properties, 995–996
interaction with ionic Ca^{2+} and calcium phosphate, 996–999
Osteochondrodysplasia, serum osteocalcin in, 1025
Osteodystrophy, renal, serum osteocalcin in, 1024–1025
Osteogenesis imperfecta, serum osteocalcin in, 1025
Osteoporosis, serum osteocalcin in, 1021–1023
Oxygen gradient
in hepatic carbohydrate metabolism, 730–732
hepatic gene expression for enzymes of carbohydrate metabolism and, 734–735
Oxytocin
immunoregulatory functions, 10
leukocyte-derived, 18

P

Paget's disease, serum osteocalcin in, 1023–1024
Parathyroid hormone, serum osteocalcin and, 1027–1028
Peptide hormones
leukocyte-derived, 15–20
production and structure, 15–18
regulation and processing, 18–20
neuroendocrine
in vitro immunoregulatory functions, 5–12
leukocyte-derived. *See* Peptide hormones, leukocyte-derived
receptors common to immune and neuroendocrine systems, 21–24
Perforin, lymphocyte, 273
analogies with other pore-forming proteins, 284–287
functional assays, 271
in lymphocyte killing of target cells, 273–280
physiological role, 289–291
similarities and differences with complement membrane attack complex, 280–284
pH
intracellular, of lymphocytes, 427–432
NH_3 transport across renal tubule epithelia and, 223–225
regulation in single cells, 359–371
H^+-translocating ATPases, 361
ion transport systems in, 318–320
membrane mechanisms, 359–371
Na^+- and Cl^--dependent cotransport functionally coupled to Cl^--HCO_3^- exchange, 369–371
Na^+-H^+, HCO_3^--Cl^- double exchange and $NaCO_3^-$-Cl^- exchange, 371

Na^+-H^+ exchange, 361–369
plasma membrane Na^+-H^+ exchanger, 364–369
Pheromones
secretion, control of, 406–407
sources, 406
types, 406
Phorbol esters, platelet activation and, 117–119
Phosphatidic acid, platelet activation and, 107
Phosphatidylinositol, metabolism, in platelets, 100–101
Phosphoinositides, breakdown, in mesangial cells, 1383
Phospholipase A_2, in lymphocyte killing of target cells, 299
Phospholipase C
activation, in platelets, 108
mesangial, 1381–1395
breakdown of phosphoinositides, 1383–1384
intracellular calcium concentration, 1384–1388
ionic changes and membrane potential, 1389–1391
modulation of activation, 1389
prostaglandin synthesis, 1391–1395
receptor studies, 1381–1383
platelet inositol phospholipid hydrolysis, 98–100
Pitts, Robert F., renal ammonium production and excretion, 186–190
Pituitary hormones, sebaceous gland activity and, 399–400, 402
Plasma proteins, synthesis and degradation, hepatic zonation, 729–730
Plasminogen activator, mesangial synthesis, 1372
Plasminogen activator inhibitor, mesangial synthesis, 1372
Platelet-activating factor, 80–82
mesangial synthesis, 1375–1376
Platelet activation
adhesion, 60
inositol phospholipid metabolism and, 110
aggregation, 61–62
calcium and, 140–141
inositol phospholipid metabolism and, 111
protein phosphorylation and, 123
calcium in, 123–141
calcium-dependent processes within platelet, 126–129
calcium influx, 135–137
calcium in stimulated platelets, 133–137
calcium in unstimulated platelets, 130–133
calcium release from intracellular stores, 133–135
cAMP and protein kinase C and, 135
functional effect of calcium ionophores and intracellular calcium chelators, 137–138
general considerations, 123–126
surface-bound calcium, 133
guanine nucleotide-binding proteins in, 93–97
inositol phospholipid metabolism and, 98–111. *See also* Inositol phospholipid metabolism
molecular mechanisms, 58–143
calcium, 123–141
guanosine nucleotide-binding proteins, 93–97
inositol phospholipid metabolism, 98–111
platelet agonists and receptors, 65–92
platelet responses, 60–64
protein phosphorylation, 111–123
platelet agonists and receptors, 63, 65–92, 141–143
adenosine diphosphate, 77–80
arachidonic acid, endoperoxides and thromboxane A_2, 74–77
collagen, 69–71
epinephrine, 84–89
fibrinogen, 89–92
inositol phospholipid metabolism and, 109
platelet-activating factor, 80–82
thrombin, 71–74
vasopressin, 83–84
von Willebrand factor, 65–69
protein phosphorylation and, 111–123. *See also* Protein phosphorylation
release reaction, 62
secretion
calcium and, 139–140
inositol phospholipid metabolism and, 110–111
protein phosphorylation and, 121–122
shape change, 60–61
calcium and, 138–139
inositol phospholipid metabolism and, 110
protein phosphorylation and, 120–121
Platelet-derived growth factor, mesangial synthesis, 1374–1375
Polyphosphoinositides, metabolism, in platelets, 101–102

Pore-forming proteins, in lymphocyte killing of target cells. *See* Perforin, lymphocyte
Potassium
in target cell killing by lymphocytes, 256–257
transport, in lymphocytes, 446–456
transport systems involved in cellular volume and pH regulation, 318–320
Pregnancy, serum osteocalcin in, 1017
Presynaptic autoreceptors, modulation of neurotransmitter release, 864–962. *See also* Neurotransmitter release
Progesterone, sebaceous gland activity and, 397–398
Prolactin, leukocyte-derived, 17
Pro-opiomelanocortin-derived peptides, somnogenic activity, 636
Prostaglandins
mesangial cell synthesis, 1391–1395
somnogenic activity, 631–632
Protein kinase C, platelet 47-kDa protein phosphorylation, 115–117
Protein phosphorylation
platelet function and, 117–123
aggregation, 123
effect of exogenous diacylglycerol and phorbol ester, 117–119
secretion, 121–122
shape change, 120–121
platelet stimulation and, 111–123
general considerations, 111–113
47-kDa protein phosphorylation and protein kinase C, 115–117
myosin phosphorylation and myosin light-chain kinase, 113–115
Proteoglycans, in lymphocyte killing of target cells, 300
Purkinje system, in ventricular arrhythmia of myocardial ischemia, 1087–1088

R

Receptor
collagen, 69
Fc, mesangial cell, 1410
fibrinogen, 90–91
growth factor
potential oncogenicity, 802–804
resistance and sensitization, oncogenes and, 813–814
laryngeal, 46–48
chemoreceptors, 47–48
mechanoreceptors, 46–47
neuroendocrine peptide hormone receptors common to immune and neuroendocrine systems, 21–24
thrombin, 72
vasopressin, 83
von Willebrand factor, 66–68
Red blood cells
Amphiuma, regulatory volume increase in, 353–355
avian, regulatory volume increase in, 346–347
dog, regulatory volume increase in, 357
duck, volume regulation by, 332–333
flavins and vitamin B_6 in, 1178–1179
human, volume regulation by, 334–335
sheep, volume regulation by, 333–334
Relaxation, cardiac. *See* Heart, relaxation
Renal osteodystrophy, serum osteocalcin in, 1024–1025
Renin, mesangial synthesis, 1370–1371
Respiration, larynx in, 33–51. *See also* Larynx, respiratory functions
Retinoids, sebaceous gland activity and, 402–403
Riboflavin, 1170–1191
absorption, 1175–1176
catabolism, excretion and secretion, 1186–1188
circulatory transport, 1177–1179
erythrocytes, 1178
plasma, 1177
deficiency, 1189–1190
in foods and supplements, 1174
historical aspects, 1171
ingestion and digestion, 1174–1176
metabolic processing and regulation, 1181–1189
nutritional implications stemming from interconnections with vitamin B_6, 1189–1190
tissue uptake and release, 1179–1181
vitamin-coenzyme interconversions, 1181–1183
Rodent
sebum secretion, measurement of, 395
suprachiasmatic circadian pacemaker, 671–699. *See also* Circadian pacemaker, suprachiasmatic

S

Sebaceous glands, 383–408
cell transition time, 391–392
control of, 395–404
androgens, 395–397

early endocrine environment and, 401
endocrine control, 395–402
estrogens, 397
glucocorticoids, 398
insulin, 399
nonendocrine factors, 403–404
pituitary, 399–400
progesterone, 397–398
retinoids, 402–403
specialized glands, 401–402
thyroid hormones, 398
function, 404–407
meibomian glands, 405
nonspecialized glands, 405
pheromonal glands, 405–407
lipid production, 392–393
measurement of activity, 391–395
proliferative activity, 391
sebum composition and secretion and gland activity, 393–395
secretion, 387–390. *See also* Sebum
size and activity, 391
structure, 384–387
ductal epithelium, 386–387
lipid-producing cells, 385–386
types, 384
unresolved questions, 407–408
Sebum, 387
composition, 387–390
sebaceous gland activity and, 393–394
excretion rate, factors affecting, 403
formation of, 387
secretion
measurement in humans, 394–395
measurement in rats, 395
sebaceous gland activity and, 394–395
Serine esterases, in lymphocyte killing of target cells, 297–299
Serotonin
release, modulation by presynaptic autoreceptors, 883–894, 919–921, 933–935, 952–956
somnogenic activity, 637–638
Signal transduction, cellular
mesangial, 1377–1396. *See also* Mesangial cell, hormonal control of
oncogene interactions with cells, 812–815
autocrine cascades, 812–813
context, 814–815
resistance and sensitization, 813–814
oncogenes and, 797–815
protooncogene proteins as components of signaling systems, 798–812
effectors, 809–810
growth factors, 800–802
modulators, 806–809
receptors, 802–804
targets, 810–812
transducers, 804–806
Skin, structure and function, 1316–1317
Sleep, laryngeal breathing movements in, 42–43
Sleep homeostasis, 608–612
rapid-eye-movement sleep, 610–611
sleep deprivation, problem of specificity, 611–612
sleep intensity, EEG slow-wave activity and, 608–610
sleep latency and sleep duration, 608
δ-Sleep-inducing peptide, 622–628
analogues, 628–629
Sleep-promoting substances, endogenous, 605
acetylcholine, 639–640
activation and deactivation of, 654–655
adenosine, 638–639
adrenal steroid metabolites, 641
arginine vasotocin, 635–636
calcium, 641–642
catecholamines, 640
changes associated with sleep and waking, 651–652
cholecystokinin octapeptide, 637
criteria for, 645
endogenous organic bromine compound, 642
factor S, 614–615
growth hormone, 633
growth hormone-releasing factor, 633–634
insulin and alterations in glucose metabolism, 634–635
interferon, 643
interleukin 1, 642–643
lipopolysaccharide and lipid A, 644
melatonin, 640–641
muramyl peptides, 615–617
Pieron's hypnotoxin theory, 613–614
pro-opiomelanocortin-derived peptides, 636
prostaglandins, 631–632
research areas, 656–657
search and identification of, 613–645
electrical brain stimulation approach, 621–629
immunologically active peptides, 642–645
neuromodulators and neurotransmitters, 631–642
rapid-eye-movement sleep deprivation approach, 620–621
spontaneous sleep approach, 629
total sleep deprivation approach, 613–619
serotonin, 637–638

δ-sleep-inducing peptide, 622–628
analogues, 628–629
sleep-promoting action, 645–651
circadian differences, 651
effective somnogenic dose and dose-response relationship, 647–648
non-rapid-eye-movement and rapid-eye-movement sleep-promoting factors, 650–651
onset and duration of action, 647
permissive vs. homeostatic, 649–650
physiological sleep, 645–646
reliability, 646
site of action, 648
species specificity, 648–649
sleep-promoting substance, 617–618
somatostatin, 634
therapeutic implications, 655–656
tumor necrosis factor, 643–644
uridine and cytidine, 618–619
vasoactive intestinal polypeptide, 632–633
Sleep regulation, physiological, processes underlying, 606–613
circadian components, 607–608
homeostatic components, 608–612. *See also* Sleep homeostasis
interaction of components, 612–613
permissive components, 606–607
Sodium
transepithelial transport in gallbladder, 504–509
across apical membrane, 517–529
across basolateral membrane, 529–532
transport, in lymphocytes, 432–446
transport systems involved in cellular volume and pH regulation, 318–320
Somatostatin
immunoregulatory functions, 11
leukocyte-derived, 18
somnogenic activity, 634
Squamous cell carcinoma, skin, 1340
Substance P, immunoregulatory functions, 11
Suprachiasmatic nuclei
afferent pathways, 674–676
functional significance, 677–680
geniculohypothalamic tract, 677–678
raphe afferents, 678–679
retinohypothalamic tract, 679–680
as circadian pacemaker, evidence for, 684–687
circadian pacemaker in rodents, 671–699. *See also* Circadian pacemaker, suprachiasmatic
efferents of, 696–699
functional considerations, 698–699
neuroanatomy, 697–698
neuropharmacology, 698
electrical activity, 689–693
responsiveness to putative neurotransmitters, 691–692
similarities to other brain areas, 692–693
spontaneous discharge of suprachiasmatic cells, 689–691
morphology and anatomy, 687–689
visual properties, 676–677
Swimming, optimization and gaits in, 1221–1224
Sympathetic neuroeffector transmission, in arteries and arterioles, 546–597
electrical properties of arteries and arterioles, 572–573
integration, 586–592
membrane properties of arterial and arteriolar smooth muscle, 550–572
neuromuscular transmission, 573–586
structure of arteries and arterioles, 548
sympathetic innervation of arteries and arterioles, 548–550
sympathetic transmitter underlying excitatory junction potentials, 592–595
terminology, 547

T

Target cells, lymphocyte killing of, mechanistic view, 250–301
Taurine, regulatory volume decrease in vertebrate cells and, 339–340
Thrombin, platelet activation and, 71–74
Thromboxane A_2, platelet activation and, 74–77
Thyroid disorders, serum osteocalcin and, 1028–1029
Thyroid hormones, sebaceous gland activity and, 398
Thyrotropin
immunoregulatory functions, 9
leukocyte-derived, 17
T lymphocytes, 2–3
cytotoxic, 251–252. *See also* Lymphocytes, killing of target cells
discrete stages of target cell killing, 254–257
membrane damage to target cells, 257–261
resistance to perforin, 287–289
proliferation, activation of, 418–419
subsets, 251
Transducers, potential oncogenicity, 804–806
Transglutaminase, keratinocyte, 1327–1329

Tumor growth factor-α, keratinocyte differentiation and, 1333
Tumor necrosis factor
in lymphocyte killing of target cells, 294, 296–297
somnogenic activity, 643–644
Turtle bladder, ammonium transport, 241–242

U

Uridine, somnogenic activity, 618
Urine, γ-carboxyglutamic acid excretion, 1014–1015

V

Vasoactive intestinal peptide
immunoregulatory functions, 11–12
leukocyte-derived, 18
Vasoactive intestinal polypeptide, somnogenic activity, 632–633
Vasoconstriction, sympathetic nerve stimulation and, 574–576
Vasopressin, platelet activation and, 83–84
Ventricular arrhythmia
chronic postinfarction, 1111–1151
animal models, 1115–1116
characteristics, 1112–1115
evidence for reentrant mechanism, 1140–1142
mapping of impulse conduction in reentrant circuits, 1142–1149
mechanisms, 1140–1149
in healing/healed infarcts, 1127–1140
inducible, 1116–1121
infarct models, 1121-
in myocardial infarction, 1119–1121
in normal hearts, 1116–1119
myocardial ischemia/infarction and, 1049–1151. *See also* Myocardial ischemia/infarction, ventricular arrhythmias in
reperfusion, 1092–1095
spontaneous, 1099–1111
electrophysiological properties of surviving Purkinje fibers, 1103–1108
mechanisms of, 1108–1111
origin of, 1102–1103
time course of occurrence and characteristics, 1099–1102
Virus infection, of keratinocytes, 1339–1340
Vitamin A
keratinocyte differentiation and, 1330–1332
sebaceous gland activity and, 402–403
Vitamin B_2. *See* Flavins; Riboflavin
Vitamin B_6, 1170–1191
absorption, 1176
catabolism, excretion and secretion, 1188–1189
circulatory transport, 1177–1179
erythrocytes, 1178–1179
plasma, 1178
deficiency, 1189–1190
in foods and supplements, 1174–1175
historical aspects, 1171
ingestion and digestion, 1174–1176
metabolic processing and regulation, 1181–1189
natural forms, 1173–1174
nutritional implications stemming from interconnections with riboflavin, 1189–1190
tissue uptake and release, 1179–1181
vitamin-coenzyme interconversions, 1183–1186
Vitamin D
keratinocyte differentiation and, 1332–1333
serum osteocalcin and, 1026–1027
Vitamin K-dependent proteins, in bone. *See* Matrix Gla protein; Osteocalcin
Von Willebrand factor, 65
collagen binding, 68–69
platelet adhesion and, 65–69
platelet receptor for, 66–68

W

Walking/running, optimization and gaits in, 1207–1218
people and animals, 1207–1216
robots, 1216–1218
Warfarin sodium, teratogenicity, 1025–1026
Weightlessness, serum osteocalcin and, 1017–1018

X

Xenobiotic metabolism
enzymes of, hepatic zonation of gene expression for, 737
hepatic zonation, 726–727
development and adaptation of zonation, 748
zonal flux differences in vitro, 748–749

Y

Yeast killer toxin, 287

Volume 69—Contents

NO. 1. JANUARY 1989

1 A Molecular Basis for Bidirectional Communication Between the Immune and Neuroendocrine Systems
J. Edwin Blalock

33 Respiratory Functions of the Larynx
Donald Bartlett, Jr.

58 Molecular Mechanisms of Platelet Activation
Wolfgang Siess

179 Ammonium Transport in the Kidney
Mark A. Knepper, Randall Packer, and David W. Good

250 Killing of Target Cells by Lymphocytes: A Mechanistic View
John Ding-E Young

NO. 2. APRIL 1989

315 Membrane Mechanisms in Volume and pH Regulation in Vertebrate Cells
Else K. Hoffmann and Lars Ole Simonsen

383 Control and Function of Sebaceous Glands
Anthony J. Thody and Sam Shuster

417 Ion Transport, Membrane Potential, and Cytoplasmic pH in Lymphocytes: Changes During Activation
Sergio Grinstein and S. Jeffrey Dixon

482 Posttranslational Processing of Gastrin
Daryl Daugherty and Tadataka Yamada

503 Ion Transport Across Gallbladder Epithelium
Luis Reuss

546 Sympathetic Neuroeffector Transmission in Arteries and Arterioles
G. D. S. Hirst and F. R. Edwards

605 Endogenous Sleep-Promoting Substances and Sleep Regulation
Alexander A. Borbély and Irene Tobler

NO. 3. JULY 1989

671 Neurophysiology of the Suprachiasmatic Circadian Pacemaker in Rodents
J. H. Meijer and W. J. Rietveld

708 Functional Specialization of Different Hepatocyte Populations
Kurt Jungermann and Norbert Katz

765 Structure and Function of Vacuolar Class of ATP-Driven Proton Pumps
Michael Forgac

797 Oncogenes and Cellular Signal Transduction
Ian G. Macara

821 Electrical Field Effects: Their Relevance in Central Neural Networks
Donald S. Faber and Henri Korn

864 Modulation of Neurotransmitter Release by Presynaptic Autoreceptors
K. Starke, M. Göthert, and H. Kilbinger
990 Osteocalcin and Matrix Gla Protein: Vitamin K-Dependent Proteins in Bone
Peter V. Hauschka, Jane B. Lian, David E. C. Cole, and Caren M. Gundberg

NO. 4. OCTOBER 1989

1049 Electrophysiological Mechanisms of Ventricular Arrhythmias Resulting From Myocardial Ischemia and Infarction
Michiel J. Janse and Andrew L. Wit
1170 Two Interconnected B Vitamins: Riboflavin and Pyridoxine
Donald B. McCormick
1199 Optimization and Gaits in the Locomotion of Vertebrates
R. McN. Alexander
1228 Relaxation and Diastole of the Heart
Dirk L. Brutsaert and Stanislas U. Sys
1316 Structure, Function, and Differentiation of the Keratinocyte
Richard L. Eckert
1347 Physiology of the Mesangial Cell
Paolo Mené, Michael S. Simonson, and Michael J. Dunn